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http://dx.doi.org/10.1016/j.jaci.2015.08.0424) by performing skin prick tests and APTs with rBet v 1 and
hypoallergenic rBet v 1 fragments. T-cell, cutaneous lymphocyte
antigen (CLA)1 and CCR41 T-cell and cytokine responses were
studied by thymidine uptake, carboxyfluorescein diacetate
succinimidyl ester staining, and Luminex technology,
respectively.
Results: rBet v 1 and hypoallergenic rBet v 1 fragments induced
APT reactions in not only most of the patients with birch pollen
allergy with AD (11/15) but also in most of those without AD (4/
5). Patients with birch pollen allergy with AD had higher Bet v
1–specific proliferation of CLA1 and CCR41 T cells compared
with patients with birch pollen allergy without AD. There were
no differences in Bet v 1–specific CLA1 and CCR41
proliferation and cytokine secretion in patients with and without
APT reactions.
Conclusion: Hypoallergenic rBet v 1 fragments induce T cell–
dependent late reactions not only in patients with birch pollen
allergy with AD but also in those without AD, which can be
determined based on APT results but not based on in vitro
parameters. (J Allergy Clin Immunol 2016;137:601-9.)
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Immediate-type inflammation caused bymast cell and basophil
activation through IgE-allergen complexes is a hallmark of IgE-
associated allergy, but there are also allergic manifestations, such
as atopic dermatitis (AD), chronic asthma, and nasal polyposis, in
which T-cell activation seems to play amajor role.1-4 Results from
clinical studies performed with drugs targeting IgE, such as oma-
lizumab, an anti-IgE antibody,5-7 and in vitro data showing that
IgE-facilitated allergen presentation8,9 is important for the
activation of allergen-specific T cells suggest that IgE-mediated
mechanisms also play a role in T cell–mediated allergic inflam-
mation. However, studies performed with non–IgE-reactive
allergen derivatives provided evidence that late-phase allergic
inflammation can be elicited without involvement of IgE in
patients with asthma, rhinoconjunctivitis, and AD.10-12
In an elegant study, Haselden et al10 have shown that late-phase
asthmatic responses can be induced by injection of T-cell epitope–
containing peptides without IgE reactivity in a T cell–dependent
and MHC-restricted manner. Late-phase allergic side effects
were also frequently observed in patients treated with chemically
modified allergen extracts termed allergoids, which displayed
reduced IgE reactivity,13 and in patients with birch pollen–induced
rhinoconjunctivitis who were treated with allergen-specific601
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thetic fragments of the major birch pollen allergen Bet v 1.12,14 In
a preliminary study we demonstrated that hypoallergenic recom-
binant fragments of the major birch pollen Bet v 1 induce atopy
patch test (APT) reactions in patients with AD exacerbations
induced by birch pollen.11 The latter studies provide evidence
for the occurrence of an IgE-independent, T cell–mediated
mechanism in late-phase allergic inflammation in allergic
patients, but it has not been studied whether this mechanism is
limited to certain allergic phenotypes/manifestations, such as
AD, or occurs also in others (eg, rhinoconjunctivitis and asthma).
Furthermore, it has not been investigated whether patients with
IgE-independent T cell–mediated inflammation can be identified,
and it is unclear what cell types, soluble factors, or both are
precisely responsible for this type of allergic inflammation.15-18
The identification of patients with IgE-independent, T cell–
mediated allergic inflammation would be important because these
patients might benefit from T cell–targeting therapeutic
strategies. Furthermore, knowledge regarding the mechanisms
underlying non–IgE-mediated allergic inflammation is important
for the design of SIT strategies that avoid T cell–mediated side
effects, which in fact seem to be very common during SIT.19,20
We conducted a clinical trial with the IgE-reactive major birch
pollen allergen rBet v 1 (amino acids 1-160) and 2 hypoallergenic
rBet v 1 fragments containing the Bet v 1–specific T-cell epitopes
(F1: amino acids 1-74 and F2: amino acids 75-160) for use in skin
prick tests (SPTs) and APTs in patients with birch pollen allergy
with and without AD to investigate whether hypoallergenic Bet v 1
fragments can induceAPTreactions in patients with defined clinical
phenotypes (ie, AD and rhinoconjunctivitis). Furthermore, we
performed an extensive analysis of T-cell and cytokine responses
and correlated these data with the presence or absence of positive
APT reactions to studywhether surrogatemarkers for the prediction
of T cell–mediated allergic inflammation can be defined.METHODS
Subjects and study design
The present study was conducted at the Department of Dermatology of the
Medical University of Vienna as a National Institutes of Health (NIH)–
registered clinical trial (2009-011859-51) with the approval of the Ethics
Committee of the Medical University of Vienna (EK147/2009) and the
Austrian health authorities in accordance with the guidelines of the
Declaration of Helsinki. Fig 1 provides a summary of the study. A total of
30 subjects (18-65 years of age) were enrolled and allocated to 4 groups.
Table I summarizes the demographic and clinical characteristics of the study
population. Group 1 comprised patients who, according to clinical history, had
exacerbation of AD during the birch pollen season (n 5 15); group 2
comprised patients with birch pollen–related rhinoconjunctivitis who had
never experienced any AD symptoms (n5 5); group 3 comprised allergic pa-
tients without birch pollen allergy (n5 5); and group 4 comprised nonallergic
subjects (n5 5, Fig 1 and Table I). The group sizes were influenced by resultsfrom a pilot study in which we found that non–IgE-reactive rBet v 1 fragments
induced positive APT results in 4 of 6 patients with birch pollen allergy.11 In
our current study the sample size per group was enlarged 5-fold for groups 1 to
3 and 2.5-fold for control group 4. Exclusion criteria are described in the
Methods section in this article’s Online Repository at www.jacionline.org.
The trial comprised 2 visits. At visit 1 (day 1), the participants were
subjected to anamnesis and clinical documentation, a blood sample was
drawn, and thereafter SPTs and APTs were performed with an equimolar mix
of F11F2 with rBet v 1. The blood samples were used for determination of
total IgE and specific IgE reactivities, for basophil activation testing, and to
study T-cell proliferation, proliferation of cutaneous lymphocyte antigen
(CLA)1, and CCR41 CD3 T cells and cytokine responses. The second visit
(day 3) took place 48 hours after skin testing and included the reading and
photodocumentation of APT reactions (Fig 1).
To investigate whether positive APT reactions to rBet v 1 or to the F11F2
mix are associated with specific cellular responses, the 30 study subjects were
regrouped according to their APT reactions and the presence or absence of
birch pollen allergy into group A (patients with positive APT reactions and
birch pollen allergy), group B (patients with lack of APT reactions and
presence of birch pollen allergy), and group C (subjects with lack of APT
reactions and absence of birch pollen allergy).
Study materials, SPTs, and APTs
Purified folded and IgE-reactive rBet v 1, as well as hypoallergenic rBet v 1
fragment 1 (F1: amino acids 1-74) and rBet v 1 fragment 2 (F2: amino acids
75-160), were produced according to good manufacturing practice guidelines
by Biomay AG (Vienna, Austria) as sterile stock solutions. Dilutions used as
test solutions were freshly prepared by the investigator shortly before testing
and used for SPTs and APTs, as described in the Methods section in this
article’s Online Repository.
Total and specific IgE levels
Serum samples were obtained from each participant at visit 1 before SPTs
and APTs were performed and stored at2208C until use. Total IgE levels and
specific IgE levels to natural birch pollen extract and rBet v 1 were measured
by using the ImmunoCAP system (Phadia, Uppsala, Sweden). IgE reactivity to
rBet v 1 and hypoallergenic rBet v 1 fragments was determined in a RAST-
based nondenaturing dot blot assay, as described in theMethods section in this
article’s Online Repository.
Lymphocyte proliferation assays and detection of
secreted cytokines
Lymphocyte proliferation assays and detection of secreted cytokines were
performed as described in the Methods section in this article’s Online
Repository. Flow cytometric analysis of CLA1 and CCR41 T cells were per-
formed as described in theMethods section in this article’s Online Repository.
Statistical analysis
The nonparametric Kruskal-Wallis test was used for comparison between
the APT-positive and APT-negative groups. In case of statistical significance,
retesting with the Mann-Whitney U test was used to assess statistical differ-
ences of pairwise comparisons between the APT-positive and APT-negative
groups. P values of less than .05 were considered statistically significant.
Basophil activation determined by means of flow
cytometry: CD203c and CD63 assay
Basophil activation was detected bymeans of flow cytometry with CD203c
and CD63 assays, as described in the Methods section in this article’s Online
Repository.
RESULTS
Characteristics of study subjects and study design
Thirty subjects (16 female and 14 male subjects) were recruited
and allocated to 4 groups (Fig 1 and Table I). Group 1 included 15
Subjects (n = 30)
Group 2 Group 3
Allergic, Birch - 
n = 15
  F/M: 8/7
Group 1
Birch +
n = 5
F/M: 2/3
n = 5 n = 5
Group 4
Non-allergic
AD +
Birch +
AD -
F/M: 16/14
F/M: 2/3 F/M: 4/1
  48h
SPT
APT reading
Visit 1 Visit 2
Blood taking
APT
FIG 1. Study design. Four groups of subjects, group 1 (patients with birch pollen allergy with AD, n 5 15),
group 2 (patients with birch pollen allergy with rhinoconjunctivitis without AD, n 5 5), group 3 (allergic
patients without birch pollen allergy and without AD, n5 5), and group 4 (nonallergic subjects, n5 5), were
subjected to SPTs and APTs.
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44 years; mean age, 28.76 6.4 years). Each of these patients also
had birch pollen–related rhinoconjunctivitis, 4 had asthma, and 9
had birch pollen-related oral allergy syndrome (Table I). Patients
from group 1 were allergic to several other allergen sources as
well (eg, house dust mites, animals, grass pollen, and molds).
Group 2 consisted of 5 patients with birch pollen–related
rhinoconjunctivitis who, like patients in group 1, were allergic to
several other allergen sources as well (eg, house dust mites,
animals, grass pollen, and molds; age, 25-47 years; mean age,
34.46 9.3 years; Table I). However, unlike patients from group 1,
group 2 patients never had AD.
Two control groups containing subjects without birch pollen
allergy were also studied. Group 3 contained 5 patients with only
respiratory allergy to allergen sources other than birch pollen
(age, 28-33 years; mean age, 30.86 1.9 years). Group 4 included
5 nonallergic subjects (age, 23-36 years; mean age,
29.8 6 5 years; Fig 1 and Table I). Table I provides a summary
of the demographic and clinical characteristics of the subjects,
whereas Table E1 in this article’s Online Repository at www.
jacionline.org shows additional serologic and immunologic pa-
rameters of the study subjects.
Each of the patients with birch pollen allergy in groups 1 and 2
showed specific IgE reactivity to rBet v 1 (group 1: median, 12.8
kUA/L; group 2: median, 13.8 kUA/L) and birch pollen extract
(group 1: median, 13.2 kUA/L; group 2: median, 12 kUA/L),
whereas subjects from groups 3 and 4 did not (see Table E1).Subjects from the 4 groups were also characterized regarding
IgE reactivity to rBet v 1, F1, F2, and F11F2 by using RAST-
based dot blotting. Each of the patients with birch pollen allergy
from groups 1 and 2 displayed IgE binding to rBet v 1, whereas
none showed IgE binding to F1 (see Fig E1 in this article’s Online
Repository at www.jacionline.org). Only 1 patient from group 2
(ie, patient 10) had a slightly positive IgE reactivity to F2 (see
Fig E1 and Table E1). Eight of the 20 patients with birch pollen
allergy from groups 1 and 2 displayed weak IgE binding (accord-
ing to densitometry, <20% of IgE reactivity to Bet v 1) to the
F11F2 mix (group 1: subjects 18, 22, 25, and 26; group 2: sub-
jects 6, 9, 10 and 13; see Fig E1). Sera from subjects of group 3
and 4 did not show any detectable IgE reactivity to dot-blotted
rBet v 1 or to hypoallergenic rBet v 1 fragments (see Fig E1). Dur-
ing visit 1, blood samples were taken from each of the 30 subjects,
SPTs were performed, and APTs were mounted, the results of
which were then read 48 hours later during visit 2.rBet v 1, but not rBet v 1 fragments, induce
immediate-type skin reactions in patients with
birch pollen allergy
SPTs demonstrated that all patients with birch pollen allergy
(groups 1 and 2) had immediate-type skin reactions to birch
pollen extract and to each of the 2 concentrations of rBet v 1 (ie,
20 and 40 mg/mL; Table II). By contrast, none of the 20 patients
with birch pollen allergy exhibited immediate-type skin reactions
TABLE I. Demographic and clinical characteristics of subjects
Characteristics of subjects Group 1 (n 5 15) Group 2 (n 5 5) Group 3 (n 5 5) Group 4 (n 5 5)
Sex
Male, no. (%) 8 (53.3) 3 (60) 3 (60) 1 (20)
Female, no. (%) 7 (46.7) 2 (40) 2 (40) 4 (80)
Age (y)
Mean 6 SD 28.7 6 6.4 34.4 6 9.3 30.8 6 1.9 29.8 6 5
Range 19-44 25-47 28-33 23-36
Allergies, no. (%)
Birch 15 (100) 5 (100) – –
Animals 14 (93.3) 5 (100) – –
Grass 12 (80) 5 (100) 3 (60) –
Plant food 9 (60) 4 (80) 1 (20) –
Non–plant-derived food 6 (40) 1 (20) – –
Molds 8 (53.3) 2 (40) 1 (20) –
Mites 14 (93.3) 4 (80) 3 (60) –
Weeds 4 (26.7) 1 (20) 1 (20) –
Symptoms, no. (%)
Atopic dermatitis 15 (100) – – –
Rhinoconjunctivitis 15 (100) 5 (100) 5 (100) –
Asthma 4 (26.7) – – –
Oral allergy syndrome 9 (60) 5 (100) – –
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allergenic rBet v 1 fragment mix (F11F2, Table II) or to the hy-
poallergenic rBet v 1 fragments F1 or F2 (data not shown).
Interestingly, none of the 8 subjects with residual IgE reactivity
to rBet v 1 fragments (see Table E1) showed any immediate
skin response to the fragments or fragment mix (Table II and
see Fig E2 in this article’s Online Repository at www.
jacionline.org). None of the control subjects (group 3: allergic
without birch pollen allergy; group 4: nonallergic) had positive
skin reactions to birch pollen extract, rBet v 1, the F11F2 mix,
or the individual fragments (Table II, data not shown). Each of
the subjects had immediate SPT responses to histamine.APT reactions to rBet v 1 and rBet v 1 fragments
occur only in patients with birch pollen allergy
In parallel to SPTs, APTs were performed on the backs of the
subjects with 160 mg of rBet v 1 or with an equimolar mix
containing 80 mg of each hypoallergenic rBet v 1 fragment
(F11F2, Fig 1). Fifteen of the 30 subjects had positive APT re-
sponses to 1 or both of the antigens. Each of the subjects with pos-
itive responses belonged to group 1 or 2 and was birch pollen
allergic, whereas none of the subjects from groups 3 or 4 had a
positive APT result (Table II). Interestingly, APT reactions were
induced by IgE-reactive antigens, as well as by hypoallergenic
rBet v 1 fragments and occurred in patients with exacerbation
of AD induced by birch pollen, as well as in patients with birch
pollen–induced respiratory allergy without AD (see Fig E3 in
this article’s Online Repository at www.jacionline.org for some
examples). APT reactions with single fragments and control
APTs performed with pure Vaseline (Unilever, London, United
Kingdom) were negative (data not shown).Frequent occurrence of APT reactions to
hypoallergenic rBet v 1 fragments in patientswithAD
We found that APTs with rBet v 1 induced an eczematous
reaction in 11 (73.3%) of 15 patients with exacerbation of ADinduced by birch pollen (group 1; Table II and Fig E3 in this arti-
cle’s Online Repository at www.jacionline.org shows subjects 19
and 26 as examples). APTs with a mix of hypoallergenic F11F2
induced a positive eczematous reaction in 10 (66.7%) of 15 pa-
tients with exacerbation of AD induced by birch pollen (group
1; Table II and Fig E3 shows an example given for subject 26).
Only 3 of the 10 subjects with positive APT reactions to the hypo-
allergenic F11F2 mix had residual IgE reactivity to the F11F2
mix, whereas the other 7 subjects had no detectable IgE specific
for F11F2. Therefore, an involvement of IgE (eg, contribution
of mast cell or basophil activation or IgE-facilitated allergen pre-
sentation) in the APT reactions can be excluded for the latter
subjects.Frequent occurrence of APT reactions to rBet v 1
and rBet v 1 fragments in patients with only
respiratory birch pollen allergy
Interestingly, we observed that APTs with rBet v 1 also induced
eczematous skin reactions in 4 (80%) of 5 patients who had only
birch pollen–related rhinoconjunctivitis but who never experi-
enced exacerbation of AD induced by birch pollen (group 2; Table
II and see Fig E3 for results for subjects 11 and 13 as example).
Again, we found that the mix of hypoallergenic F11F2 induced
eczematous skin reactions in 3 of the 5 patients with birch pollen
allergy who had only respiratory forms of birch pollen allergy
without AD (group 2; Table II and see Fig E3 for subject 13 shown
as an example).Neither rBet v 1– nor rBet v 1 fragment–specific
T-cell proliferation were significantly associated
with the occurrence of APT reactions
In a first set of experiments, we analyzed lymphocyte prolif-
eration toward rBet v 1 and hypoallergenic F11F2 in subjects of
groups 1 to 4 (Fig 2, upper panel).We found that rBet v 1–induced
T-cell proliferation was significantly higher in patients with exac-
erbation of AD induced by birch pollen (group 1) compared with
TABLE II. SPT and APT responses
Subject Group
SPT (mm2) APT
Histamine Birch
rBet v 1
(20 mg/mL)
rBet v 1
(40 mg/mL)
F11F2
(20 mg/mL)
F11F2
(40 mg/mL) rBet v 1 F11F2
1 1 82.29 124.80 134.32 152.70 2 2 1 1 1 1 1 1 1 1
5 1 76.26 91.27 56.64 76.57 2 2 1 1 1 1 1
7 1 157.06 173.38 190.06 187.13 2 2 1 1 1 1 1
8 1 184.98 137.88 201.50 220.83 2 2 1 1 1 1 1 1 1 1
15 1 115.17 152.10 104.68 236.41 2 2 1 1 1 1 1
18 1 37.20 62.84 67.17 84.41 2 2 1 1 1 1 1 1 1 1 1 1
20 1 102.79 139.73 95.90 111.55 2 2 1 1 1 1
21 1 40.38 46.49 39.09 42.69 2 2 1 1 1 1
22 1 148.30 87.79 122.01 170.25 2 2 1 1 1 1 1 1 1 1 1 1
26 1 59.59 64.79 49.70 94.92 2 2 1 1 1 1 1 1 1 1 1 1
19 1 144.71 96.06 141.87 223.65 2 2 1 1 2
24 1 50.68 50.52 61.33 78.70 2 2 2 2
25 1 236.38 235.59 227.69 394.59 2 2 2 2
27 1 115.47 120.12 242.12 243.92 2 2 2 2
28 1 128.67 137.17 191.41 267.77 2 2 2 2
9 2 121.10 217.00 201.28 410.51 2 2 1 1 1 1 1 1 1
10 2 54.56 56.20 51.12 61.84 2 2 1 1 1 1 1 1
13 2 116.13 104.07 132.37 324.44 2 2 1 1 1 1 1 1 1 1
11 2 133.51 119.15 190.26 285.30 2 2 1 1 2
6 2 120.78 108.69 73.00 89.83 2 2 2 2
2 3 122.58 2 2 2 2 2 2 2
3 3 192.57 2 2 2 2 2 2 2
4 3 89.89 2 2 2 2 2 2 2
12 3 76.05 2 2 2 2 2 2 2
23 3 66.26 2 2 2 2 2 2 2
14 4 51.2 2 2 2 2 2 2 2
16 4 79.89 2 2 2 2 2 2 2
17 4 43.62 2 2 2 2 2 2 2
29 4 197.43 2 2 2 2 2 2 2
30 4 142.45 2 2 2 2 2 2 2
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also significantly higher in patients with respiratory allergy to
birch without AD and allergic patients without birch pollen al-
lergy compared with that in nonallergic subjects (Fig 2, upper
panel). However, no significant differences were observed when
groups 1, 2, and 3 were compared with each other. Furthermore,
no statistically significant differences regarding T-cell prolifera-
tions specific for hypoallergenic F11F2 among groups 1 to 4
were found (Fig 2, upper panel).
We did not find any statistically significant differences
regarding T-cell proliferation to rBet v 1 and the mix of
hypoallergenic F11F2 when the 30 study subjects were re-
grouped according to the presence of APT reactions and birch
pollen allergy (ie, groupA), lack of APT reactions and presence of
birch pollen allergy (ie, group B), and lack of APT reactions and
absence of birch pollen allergy (ie, group C; Fig 2, lower panel).Proliferation of Bet v 1–specific skin-homing T cells
is highest in patients with birch pollen allergy with
AD but is not significantly correlated with positive
APT reactions
It is well established that patients with AD have increased
levels of skin-homing CLA1 andCCR41T cells.21 However, thus
far, it has not been studied whether there is an association between
allergen-induced proliferation of these cells and allergen-inducedeczematous skin reactions. We found that stimulation with rBet v
1 induced a specific CD31CD41 cell proliferation in the CLA1
and CCR41 cells that was significantly higher in the group of pa-
tients with exacerbations of AD induced by birch pollen
compared with groups 2, 3, and 4 (ie, subjects without birch pol-
len–induced AD; Fig 3, A). A similar trend was observed when
cells were stimulated with the mix of hypoallergenic F11F2 for
CCR41 cells (Fig 3,B). The proliferation was significantly higher
in group 1 when compared with that in groups 2 and 3 but was not
significant when compared with that in group 4. For CLA1 cells,
differences were not significant.
Interestingly, when patients with birch pollen allergy were
regrouped according to the occurrence (ie, group A) or absence
(ie, group B) of a positive APT reaction, there was no significant
difference between the groups regarding proliferation induced
with Bet v 1 in CLA1 and CCR41 cells and also proliferation
induced with the mix of hypoallergenic F11F2 in CLA1 and
CCR41 cells (Fig 3, C and D).Patients with birch pollen allergy with and without
Bet v 1–specific APT reactions have similar cytokine
responses to Bet v 1 and Bet v 1 fragments
No statistically significant differences were found regarding
levels of any of the cytokines (ie, IL-1, IL-2, IL-4; IL-5, IL-6, IL-
7, IL-8, IL-10, IL-12, IL-13, IL-17, IL-22, IFN-g, TNF-a,
0
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BA C
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1 2 3 4
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0
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FIG 2. T-cell proliferation toward rBet v 1 or F11F2. Shown are PBMC proliferations (y-axes: stimulation
indices as box-and-whisker plots showing minimum, quartiles, median, and maximum values) in response
to rBet v 1 or the rBet v 1 fragments (F11F2) for study groups 1 to 4 (upper panel) and (lower panel) for
patients with birch pollen allergy with positive APT reactions (group A), patients with birch pollen allergy
with negative APT reactions (group B), and subjects without birch pollen allergy with negative APT
reactions (group C). Significant differences between the groups are indicated.
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606 CAMPANA ET ALgranulocyte colony-stimulating factor, GM-CSF, monocyte che-
moattractant protein 1, and macrophage inflammatory protein 1)
induced in PBMCs with rBet v 1 (see Fig E4 in this article’s On-
line Repository at www.jacionline.org) or with the hypoallergenic
F11F2 mix (see Fig E5 in this article’s Online Repository at
www.jacionline.org) from patients with positive APT reactions
(ie, group A) compared with those from patients with negative
APT reactions (ie, groupB: birch pollen allergy; groupC: absence
of birch pollen allergy). Yet some other differences were noted
that were not related to the presence or absence of ATP reactions.
For example, hypoallergenic F11F2 induced significantly higher
levels of the TH1 cytokine IFN-g in PBMCs from patients without
birch pollen allergy (see Fig E5). A similar trend without signif-
icance was observed for Bet v 1 (see Fig E4). An inverse situation
was found for IL-4 levels, which were significantly higher in
PBMCs from patients with birch pollen allergy stimulated with
the mix of hypoallergenic F11F2 (see Fig E5). A similar trend
without significance was found for Bet v 1 (see Fig E4). In accor-
dance with the results for IFN-g and IL-4, we found that levels of
IL-12 induced with Bet v 1 and the mix of hypoallergenic F11F2
were highest in PBMC cultures from subjects without birch pol-
len allergy. The latter findings thus seem to reflect the TH1/TH2dysbalance of the Bet v 1–specific response in subjects with
and without birch pollen allergy.
Interestingly, IFN-g levels were significantly higher in PBMCs
of the patients with birch pollen allergy with positive APT
reactions (ie, group A) when compared with those in patients with
birch pollen allergy without positive APT reactions (ie, group B)
when the mix of hypoallergenic F11F2 was used for stimulation.
However, IFN-g levels were also significantly higher in PBMCs
of subjects without birch pollen allergy and negative APT
reactions (ie, group C) when compared with those in patients
with birch pollen allergy without positive APT reactions (ie,
group B).
Furthermore, we noted that IL-7 levels in PBMC cultures from
patients with birch pollen allergy stimulated with Bet v 1 and the
mix of hypoallergenic F11F2were significantly higher compared
with levels found in cultures of PBMCs from subjects without
birch pollen allergy (see Figs E4 and E5).
We also studied whether supernatants from stimulated PBMCs
of the study subjects would be able to activate basophils by
studying upregulation of basophil activation markers (ie, CD63
and CD203c). However, we could not detect any increase in
upregulation of these markers when basophils were exposed to
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FIG 3. Activation of CLA1 or CCR41CD31 cells by rBet v 1 or F11F2 with carboxyfluorescein diacetate
succinimidyl ester staining. A and B, Shown are the stimulation indices as box-and-whisker plots showing
minimum, quartiles, median, and maximum values in response to rBet v 1 (Fig 3, A) or to the rBet v 1
fragment mix (F11F2; Fig 3, B) for study groups 1 to 4. C and D, Results for patients with birch pollen allergy
with positive APT reactions (Fig 3, A), patients with birch pollen allergy with negative APT reactions (Fig 3,
B), and subjects without birch pollen allergy with negative APT reactions (Fig 3, C) in response to rBet v 1
and F11F2, respectively. Significant differences between the groups are indicated. The horizontal dashed
line represents the cutoff for positive proliferation (stimulation index > 1).
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mix compared with medium (data not shown).DISCUSSION
In this clinical study we used hypoallergenic T-cell epitope–
containing fragments of the major birch pollen allergen Bet v 1 to
investigate the occurrence of IgE-independent, T cell–mediated
allergic skin inflammation in patients with birch pollen allergy
with different disease manifestations, allergic patients without
birch pollen allergy, and nonallergic subjects by using APTs. We
found that 11 (73.3%) of 15 patients with birch pollen allergy
with AD had T cell–mediated APT reactions to rBet v 1, and 10 of
these patients (10/15 [66.6%]) had late eczematous reactions to
the mix of hypoallergenic rBet v 1 fragments. These results
demonstrate that non–IgE-mediated mechanisms are very
frequent in chronic allergen-induced skin inflammation. More
important, and quite unexpected, was the finding that T cell–
mediated APT reactions to rBet v 1 (4/5 [80%]) were also very
common in patients with birch pollen allergy who had only
allergic rhinoconjunctivitis but never experienced an exacerba-
tion of AD induced by birch pollen. Here again, the eczematous
reactions were often IgE-independent, appearing in 3 (60%) of 5
patients. In fact, there are not many studies in which APTs were
performed with allergen extracts in allergic patients without AD,
and there is no systematic study in which hypoallergenic allergen
derivatives were used for APTs. In studies comparing allergic
patients with and without AD, positive APT reactions were much
more frequent in patients with AD or confined to this group when
compared with patients with only respiratory allergy without
a history of eczema.22 In our study, the appearance of Bet v
1–specific APT reactions was strictly confined to patients with
birch pollen allergy and was not observed in allergic patients
without birch pollen allergy or nonallergic subjects. In fact, others
have reported that positive APT reactions to aeroallergens are
very common in patients with AD,23 but our study is the first to
use hypoallergenic allergen derivatives to demonstrate that the
reactions are often non–IgE mediated. Even for those patients
who showed some residual IgE reactivity to the mix of rBet v 1
fragments (ie, <20% of the Bet v 1–specific IgE reactivity), it is
very unlikely that the APT reactions were IgE mediated because
the magnitudes of the APT reactions were similar between those
induced by fully IgE-reactive Bet v 1 and those induced by the
hypoallergenic Bet v 1 fragments, despite extremely low IgE
reactivity of the rBet v 1 fragments and their lack of allergenic
activity, as shown by SPTs.
According to the type of reaction (ie, hypersensitivity type IV
like) and the time of appearance (ie, 48 hours after application,
delayed type), the APT reactions were most likely T cell
mediated. Therefore we searched for surrogate markers of Bet v
1–specific T-cell activation and Bet v 1–specific induction of
T cell–derived cytokines, which might be associated with the
APT reactions. Much to our surprise, we did not find any
significant correlation between positive Bet v 1–specific APT
reactions and Bet v 1–specific T-cell proliferation in cultured
PBMCs. Because in the present study we could analyze only
T-cell and cytokine responses in peripheral blood, we next sought
to focus on T cells that home to the skin and express CLA, CCR4,
or both.24,25 In fact, it has been reported that CLA1CCR41T cells
are upregulated in lesional skin of patients with AD, but it has notyet been investigated whether allergen-induced activation of
such cells is associated with allergen-induced APT reactions.
We found an increased expression of skin-homing (CLA1) and
CCR41CD41 T cells in the rBet v 1–stimulated PBMCs from
patients with AD compared with those from patients with only
birch pollen–related rhinoconjunctivitis and nonallergic subjects.
These results are comparable with those of Nakatani et al,21
indicating a predominant expression of skin-homing cells in the
peripheral blood of patients with AD. However, again,
analysis of allergen-specific activation and proliferation of
in vitro–cultured skin-homing cells in patients with positive
allergen-specific APT reactions were not significantly correlated.
In our analysis we investigated only CD31CD41 T cells. There-
fore it is possible that the development of positive APT reactions
might be due to other types of T cells, such as CD81 T cells,
which were reported to occur in increased numbers in patients
with positive APT reactions when compared with numbers in
normal skin,25 and there is evidence that allergen-primed CD81
T cells are required for the development of AD-like lesions.24
We also performed an extensive analysis of inflammatory and
tolerogenic cytokines, including IL-10 and IL-22, which has been
suggested to be secreted specifically by a subset of human
skin-homing T cells26 in supernatants of PBMCs stimulated
with rBet v 1 and recombinant hypoallergenic Bet v 1 fragments.
However, we did not find significant correlations between any of
the tested allergen-induced cytokines and the presence or absence
of allergen-specific APT reactions.
Together with studies performed in patients with AD using Bet
v 1–homologous food allergens, which are not stable when
cooked or digested in the gastrointestinal tract,27,28 our study
provides evidence that non–IgE-mediated, T cell–mediated
mechanisms are very common in patients with AD. It has been
also shown for patients with allergen-induced asthma that
non–IgE-mediated, T cell–dependent late-phase reactions can
occur when patients are exposed to T-cell epitope–containing
non–IgE-reactive allergen derivatives.10 Interestingly, our study
also shows that hypoallergenic Bet v 1 derivative–induced APT
reactions occur frequently in patients with birch pollen–induced
rhinoconjunctivitis. Since it has been reported that patients who
were treated with recombinant and synthetic hypoallergenic Bet
v 1 fragments frequently experience late-phase side effects,12,14
it is very likely that these side effects are non–IgE mediated
and T cell dependent. Thus our study shows that APTs with
hypoallergenic allergen derivatives but no other of the tested
in vitro surrogate markers are useful to identify patients who
show T cell–mediated allergic inflammation. Therefore one
might consider using APTs with hypoallergens to identify
patients who are at risk of having non–IgE-mediated, T cell–
mediated allergic inflammation because they might benefit from
T cell–targeted therapeutic strategies. Furthermore, patients
with T cell–mediated side effects during SIT might benefit from
new forms of SIT, which reduce the presence of allergen-
specific T-cell epitopes in the vaccine, such as recombinant
peptide carrier vaccines that have a strongly reduced ability to
induce allergen-specific T-cell activation and APT reactions.29,30
Therefore it will be interesting to perform follow-up studies in
which APTs are performed before SIT with hypoallergenic Bet
v 1 derivatives to determine whether positive APT reactions
elicited by hypoallergenic Bet v 1 derivatives might predict
late-phase side effects during birch pollen SIT.
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Subjects
Exclusion criteria were general maladies, severe skin inflammation,
pregnancy and/or lactancy, autoimmune diseases, contraindication for adren-
aline, long-term use of systemic corticosteroids, intake of immunosuppressive
or psychoactive drugs, a positive SPT response to hypoallergenic Bet v 1
fragments, simultaneous participation in another clinical study, and risk of
noncompliance with study procedures and restrictions. Use of antihistamines
within the previous 3 days and use of systemic short-term and topical
corticosteroids in the tested areawithin the previous 14 days were not allowed.
Participants signed informed consent forms before inclusion in the study.
Study materials, SPTs, and APTs
SPTs were conducted with commercial birch pollen extract (Stallergenes,
Antony, France), purified rBet v 1, and 2 hypoallergenic rBet v 1 fragments (F1
and F2 each or as the equimolar mix F11F2), which together comprise the
complete Bet v 1 sequence.E1 Concentrations were 20 and 40mg/mL (rBet v 1,
each of the fragments), as well as an equimolar mix of F11F2 containing 10
and 20 mg/mL of each fragment. Aliquots of 20 mL were applied in duplicates
on the left and right side of the forearm of the subjects at a distance of more
than 2 cm between individual application points. As controls, 1 mg/mL hista-
mine hydrochloride (positive) and sodium chloride solution (negative, Staller-
genes) were used. After 20 minutes, wheal-and-flare reactions were
photodocumented, pen marked, and transferred with scotch tape to a paper.
Themean wheal area of duplicate tests was calculated by using digital planim-
etry. Only wheals of more than 4 mm in diameter were regarded as positive
reactions.
For APTs, birch pollen extract (Stallergenes), as well as rBet v 1 (160 mg),
rBet v 1 fragment 1 (160 mg), rBet v 1 fragment 2 (160 mg), and an equimolar
rBet v 1 fragment mix (80 mg of each rBet v 1 fragment), were applied for
48 hours in patch test chambers (12 mm in diameter; Finn Chambers on
Scanpor, Large, Epitest Ltd Oy) onto nonlesional skin on the backs of the
subjects. The skin of the subjects was stripped shortly before with a tape.
A patch containing pure Vaseline petroleum jelly (Unilever) was used as a
negative control. After 48 hours, patches were removed, and reactions were
analyzed and photodocumented. Grading of positive APT reactions were done
according the European Task Force on Atopic Dermatitis by a blinded
investigator: -, negative result; ?, only erythema, questionable; 1, erythema,
infiltration;11, erythema, few papules (<_3);111, erythema, papules from
4 to less than many; 1111, erythema, many or spreading papules;
or 11111, erythema, vesicles.E2
Total and specific IgE levels
Nitrocellulose strips (Whatman Protran nitrocellulose membrane; Sigma-
Aldrich, St Louis, Mo) containing 2-mL aliquots (ie, 1 mg of rBet v1, rBet v 1
fragment 1, rBet v 1 fragment 2, an equimolar mix of the rBet v 1 fragments 1
and 2 [ie, 0.5mg each], and BSA) were incubated overnight with sera from the
30 study participants (1:10 in gold buffer) or with buffer without addition of
serum. IgE reactivity was determined, as previously described.E3 Signals ob-
tained from the dot blots were quantified by means of densitometry with Na-
tional Institutes of Health ImageJ software analysis, as described previously.E4
Lymphocyte proliferation assays and detection of
secreted cytokines
PBMCs were isolated from heparinized blood samples by means of Ficoll
density gradient separation (Amersham, GE Healthcare, Buckinghamshire,
United Kingdom). PBMCs were stimulated with 5 mg/well of rBet v 1 or an
equimolar mix of hypoallergenic rBet v 1 fragments (F11F2) in triplicates
at a density of 2 3 106 cells/well in 96-well round-bottom plates (Thermo
Fischer Scientific, Roskilde, Denmark). Cells were cultured in 200 mL of
Ultra Culture Medium (Lonza, Verviers, Belgium) supplemented as previ-
ously described.E5 Wells containing 4 units of human IL-2 each (Roche Di-
agnostics GmbH, Mannheim, Germany) or medium alone were used as
positive and negative controls, respectively. Cells were incubated for6 days in a humidified atmosphere containing 5% CO2 at 378C. Proliferation
was measured based on tritiated thymidine uptake (0.5 mCi/well; Perki-
nElmer, Boston, Mass) after 16 hours of culture. Radioactivity was
measured in counts per minute. The results were displayed as the stimula-
tion index, which was calculated as the quotient of counts per minute in
stimulated and unstimulated cultures. A response was considered positive
when the stimulation index was greater than 1.
Supernatants from equally prepared PBMC cultures were harvested at day
6, and IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17, INF-
g, TNF-a, C-GSF, GM-CSF, monocyte chemoattractant protein 1, and
macrophage inflammatory protein 1 levels were measured with the Bio-Plex
Pro human cytokine 17-plex immunoassay (Bio-Rad Laboratories, Hercules,
Calif). In addition, IL-22 levels were measured in each sample by using the
FlowCytomix Human IL-22 Simplex Kit (eBioscience, San Diego, Calif).
Cytokine values were log transformed before statistical analysis because their
distributions were asymmetric.
Flow cytometric analysis of CLA1 and CCR41 T cells
PBMCs were isolated as described above and stained with carboxy-
fluorescein diacetate succinimidyl (Invitrogen, Oslo, Norway; 1 mL of
5 mmol/L carboxyfluorescein diacetate succinimidyl ester solution per
10 3 106 cells) for 10 minutes at 378C. The labeling reaction was stopped
by adding FBS (GIBCO, Invitrogen, Carlsbad, Calif) for 5 minutes. Labeled
cells were washed with medium and cultured in triplicates (2 3 106 cells/
well) with rBet v 1 (5 mg/well), equimolar mix of hypoallergenic rBet v
1 fragments (F11F2), medium alone (negative control; Lonza, Verviers,
Belgium), or 3 mL/well of Dynabeads containing anti-CD3 and anti-CD28
(positive control, Invitrogen) for 7 days at 378C. At day 7, cells were centri-
fuged and incubated in 50 mL of solution containing 7-amino-actinomycin
D (3 mL/well; BioLegend, San Diego, Calif) plus 10 mL/well of biotin
mouse anti-human CD194 (Anti-CCR4) or biotin rat anti-CLA (BD Biosci-
ences, San Jose, Calif) diluted in fluorescence-activated cell sorting (FACS)
buffer (PBS, 0.01% wt/vol NaN3, and 1% wt/vol BSA) for 20 minutes on
ice. For control purposes, a biotin rat IgM isotype (CLA isotype) and a
mouse IgG1 isotype (CCR4 isotype, BD Bioscience) were used. Cells
were then centrifuged and stained with 1 mL/well of streptavidin-
phycoerythrin-cyanine 7 (PC7-Streptavidin, BD Biosciences) diluted in
FACS buffer for 20 minutes on ice. After centrifugation, cells were resus-
pended in FACS buffer and measured with a Cytomics FC 500 flow cytom-
eter (Beckman Coulter, Fullerton, Calif). Data analysis was done with
FlowJo Version 7.2.5 (TreeStar, Ashland, Ore). The gating strategy was
based on forward and side scatter. 7-Amino-actinomycin D (BioLegend)
was used for dead-cell exclusion. Mean percentages of CLA1CD31 and
CCR41CD31 T cells were calculated. The results were presented as stimu-
lation indices calculated as the quotient of mean percentages of CD31
T cells expressing CLA or CCR4 in stimulated and medium-only cultures.
Basophil activation by means of flow cytometry:
CD203c and CD63 assay
Peripheral blood was obtained from a donor in heparinized tubes after
informed consent was provided. Blood aliquots (100 mL) were incubated
(triplicates) for 15 minutes at 378C with 10-mL supernatants from PBMC
cultures stimulated with rBet v1, rBet v 1 F11F2, and medium and then
washed in PBS containing 20 mmol/L EDTA (Gibco). Anti-IgE mAb E-
124.2.8 (1 mg/mL) or PBS were used as controls. Thereafter, cells were
incubated with 5 mL of phycoerythrin-conjugated CD203c mAb 97A6 and
5 mL of fluorescein isothiocyanate–labeled CD63 mAb CLB-gran12 for
15 minutes at room temperature. After erythrocyte lysis with FACS Lysing
Solution (Becton Dickinson Biosciences, San Jose, Calif), cells were washed,
resuspended in PBS, and analyzed by means of 2-color flow cytometry on a
FACScan (Becton Dickinson Biosciences) with FlowJo software (Tree Star).
Anti-IgE–induced upregulation of CD203c/CD63 was calculated from mean
fluorescence intensities (MFIs) obtained with stimulated (MFIstim) and unsti-
mulated (MFIcontrol) cells and expressed as the stimulation index
(MFIstim:MFIcontrol).
E6
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FIG E1. IgE reactivity to rBet v 1 and rBet v 1 fragments. Dot-blotted purified recombinant antigens (rBet v 1,
rBet v 1 fragments F1 and F2, an rBet v 1 fragment mix [F11F2], and BSA) were incubated with sera from the
study subjects from groups 1 to 4 (1-30) or with buffer alone as a negative control (NC). Bound IgE anti-
bodies were detected with iodine 125–labeled anti-human IgE antibodies and visualized by means of
autoradiography.
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FIG E2. Immediate-type skin reactions to rBet v 1 and rBet v 1 fragments in subjects with residual IgE
reactivity to the F11F2mix in RAST-based dot blotting assay. SPTs were performedwith birch pollen extract
(1), rBet v 1 (2 and 3), and the mix of rBet v 1 fragments F11F2 (4 and 5). SPTs were performed with antigen
concentrations of 20 mg/mL (2 and 4) or 40 mg/mL (3 and 5).
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FIG E3. Delayed-type skin reactions to rBet v 1 and rBet v 1 fragments in selected subjects. Shown are APT
reactions to rBet v 1 and the rBet v 1 fragment mix (F11F2) in patients from study groups 1 to 4 (group 1,
subjects 26 and 19; group 2, subjects 13 and 11; group 3, subject 4; and group 4, subject 16). APTs were
performed with 160 mg of rBet v 1 and a mix containing 80 mg of each rBet v 1 fragment (F11F2).
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FIG E4. Cytokine levels measured in PBMC cultures on stimulation with rBet v 1 shortly before SPTs and
APTs. Shown are cytokine levels (in picograms per milliliter) determined for triplicate cultures as box-and-
whisker plots showing minimum, quartiles, median, and maximum values (y-axes) for APT-positive
patients with birch pollen allergy with positive APT reactions (A), patients with birch pollen allergy with
negative APT reactions (B), and subjects without birch pollen allergy with negative APT reactions (C;
x-axes). Statistically significant differences (P < .05) are indicated. G-CSF, Granulocyte colony-stimulating
factor; MCP-1, monocyte chemoattractant protein 1; MIP-1b, macrophage inflammatory protein 1.
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FIG E5. Cytokine levels measured in PBMC cultures on stimulation with the F11F2 mix shortly before SPTs
and APTs. Shown are cytokine levels (in picograms per milliliter) determined for triplicate cultures as box-
and-whisker plots showing minimum, quartiles, median, and maximum values (y-axes) for APT-positive
patients with birch pollen allergy with positive APT reactions (A), patients with birch pollen allergy
with negative APT reactions (B), and subjects without birch pollen allergy with negative APT reactions (C;
x-axes). Statistically significant differences (P < .05) are indicated. G-CSF, Granulocyte colony-stimulating
factor; MCP-1, monocyte chemoattractant protein 1; MIP-1b, macrophage inflammatory protein 1.
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TABLE E1. Clinical and serologic characterization of subjects
Group Subject Sex/age (y) Allergies Symptoms Total IgE (kU/L)
IgE CAP (kUA/L) IgE reactivity
Birch rBet v 1 rBet v 1 F11F2 F1 F2
1 1 F/36 b, a, g, pf, mo, mi AD, RC, OAS, AS 934 3.52 5.5 1 2 2 2
1 5 F/32 b, a, mi AD, RC 55.6 0.72 0.76 1 2 2 2
1 7 M/29 b, a, g, pf, mi AD, RC, OAS 84.2 8 5.76 1 2 2 2
1 8 M/26 b, a, g, mo, mi AD, RC 590 11.38 12.82 1 2 2 2
1 15 F/26 b, a, g, mo, mi AD, RC 522 37.4 41.2 1 1/2 2 2
1 18 M/30 b, a, g, pf, npf, mo, mi, w AD, RC, OAS 4,788 100.2 93.4 1 1 2 2
1 20 M/24 b, a, g, pf, npf, mi, w AD, RC, OAS 240 31.2 6.62 1 2 2 2
1 21 F/22 b, a, g, pf, mi AD, RC, OAS, AS 248 7.1 6.78 1 2 2 2
1 22 F/19 b, a, g, pf, npf, mo, mi AD, RC, OAS 742 46.8 49 1 1 2 2
1 26 M/31 b, a, g, pf, npf, mo, mi, w AD, RC, OAS 3,198 122.4 125.6 1 1 2 2
1 19 M/22 b, a, g, pf, npf, mo, mi, w AD, RC, OAS, AS 446 8.26 7 1 2 2 2
1 24 F/44 b, a, g, pf, npf, mi AD, RC, AS 13,840 52.8 30.2 1 2 2 2
1 25 F/26 b, a AD, RC, OAS 29 13.24 13.6 1 1/2 2 2
1 27 F/28 b, g, mi AD, RC 388 36.4 39 1 2 2 2
1 28 M/35 b, a, mo, mi AD, RC 17.96 0.7 0.7 1 2 2 2
2 9 M/25 b, a, g, pf, mo, mi RC, OAS 90.8 6.6 6.44 1 1/2 2 2
2 10 M/34 b, a, g, pf, npf, mo, mi, w RC, OAS 44.6 4.76 3.18 1 1/2 2 1/2
2 13 F/41 b, a, g, pf, mi RC, OAS 392 47.4 61 1 1 2 2
2 11 M/47 b, a, g RC, OAS 42 12 13.78 1 2 2 2
2 6 F/25 b, a, g, pf, mi RC, OAS 412 36 39.4 1 1 2 2
3 2 F/30 g, w RC 39 <0.35 <0.35 2 2 2 2
3 3 M/33 g, pf, mi, mo RC 52.6 <0.35 <0.35 2 2 2 2
3 4 M/32 mi RC 2,552 <0.35 <0.35 2 2 2 2
3 12 M/31 mi RC 450 <0.35 <0.35 2 2 2 2
3 23 F/28 g RC 1,708 <0.35 <0.35 2 2 2 2
4 14 F/27 No 2 <2 <0.35 <0.35 2 2 2 2
4 16 F/30 No 2 47.8 <0.35 <0.35 2 2 2 2
4 17 F/33 No 2 <2 <0.35 <0.35 2 2 2 2
4 29 M/23 No 2 21.8 <0.35 <0.35 2 2 2 2
4 30 F/36 No 2 7.1 <0.35 <0.35 2 2 2 2
Allergies: a, Animals; b, birch; g, grass; mi, mites; mo, molds; npf, non–plant-derived food; pf, plant food; w, weeds.
Symptoms: AD, Atopic dermatitis; AS, asthma; OAS, oral allergy syndrome; RC, rhinoconjunctivitis.
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